DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20222889
Published: 2022-10-28

Management of critically ill septic patients with diabetes

Arnab Choudhury, Sahil Kumar, Nitin Kumar, Mukesh Bairwa

Abstract


Diabetes and sepsis are major contributors of morbidity and mortality around the world, with diabetic patients accounting for the majority of post-sepsis comorbidities and escalating mortality rates. Diabetes is undoubtedly a key comorbid syndrome due to its high frequency and propensity to affect critical parts of sepsis pathogenesis; however, the precise impact of diabetes on infection and sepsis progression is elusive. In diabetic individuals with sepsis, dysfunctional immunological pathways, which are frequent in both sepsis and diabetes, promotes worsening of the host response. The effect of diabetes on sepsis mortality is still debatable. While poor glycemic management is linked to the incidence of a large proportion of severe infections, treatment with insulin or commercially available oral antidiabetic drugs are linked to lower sepsis incidence and even death. Optimal glycemic control has been reported to improve immunological adaptability, resulting in a lower mortality rate in diabetes patients with sepsis. The present review is an attempt to gather literature pertinent to glycemic control and risk of sepsis. An additional body of reports are also included on the effect of insulin and other anti-diabetic medications on the incidence and mortality for sepsis along with the strategies employed for the management of the said illness.

 


Keywords


Type 2 diabetes mellitus, Sepsis, Randomized trial, Insulin, Metanalysis, Hyper-glycemia

Full Text:

PDF

References


Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41:1167-74.

Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014;5:4-11.

Kahn JM, Le T, Angus DC, Cox CE, Hough CL, White DB et al. The epidemiology of chronic critical illness in the United States. Crit Care Med. 2015;43:282-7.

Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug-based therapeutics. Biomed Pharmacother. 2020;131:110708.

Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis. 2006;6:438-46.

Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007;23:3-13.

Bosmann M, Ward PA. The inflammatory response in sepsis. Trends Immunol. 2013;34:129-36.

Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011;378:169-81.

Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med. 2009;15:496-7.

Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776-87.

Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20:195-203.

Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-7.

Monge L, Gnavi R, Carnà P. Incidence of hospitalization and mortality in patients with diabetic foot regardless of amputation: a population study. Acta Diabetol. 2020;57:221-8.

Padhi S, Dash M, Behera A. Nanophytochemicals for the treatment of type II diabetes mellitus: a review. Environ Chem Lett. 2021;19:1.

Tiwari S, Pratyush DD, Gahlot A, Singh SK. Sepsis in diabetes: a bad duo. Diabetes MetabSyndr. 2011;5:222-7.

Frydrych LM, Fattahi F, He K. Diabetes and sepsis: risk, recurrence, and ruination. Front Endocrinol (Lausanne). 2017;8:1-22.

Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26:510-3.

Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care. 2001;24:1044-9.

Stacey HJ, Clements CS, Welburn SC, Jones JD. The prevalence of methicillin-resistant Staphylococcus aureus among diabetic patients: a meta-analysis. Acta Diabetol. 2019;56:907-21.

Finfer A, Chittock D, Su S. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283-97.

Wang Z, Ren J, Wang G. Association between diabetes mellitus and outcomes of patients with sepsis: a meta-analysis. Med Sci Monit. 2017;23:3546-555.

Goldstein DE, Little RR, Lorenz RA. Tests of glycemia in diabetes. Diabetes Care. 2004;27:1761-73.

Braithwaite SS. Through the eyes of the A1C: a call to re-examine stress hyperglycemia. Crit Care Med. 2010;38:717-9.

Waeschle RM, Moerer O, Hilgers R, Herrmann P, Neumann P, Quintel M. The impact of the severity of sepsis on the risk of hypoglycaemia and glycaemic variability. Crit Care. 2008;12(5):R129.

Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N et al. German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358(2):125-39.

NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283-97.

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.

Critchley JA, Carey IM, Harris T. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care. 2018;41:2127-35.

Karagiannis E. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabet Tech Therap. 2008;10:206-12.

Garnett JP. Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose. Thorax. 2013;68:835-45.

Song F, Zhong L, Han L, Xie G, Xiao C, Zhao B et al. Intensive Insulin Therapy for Septic Patients: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int. 2014;1-10.

Shih CJ, Wu YL, Chao PW. Association between use of oral anti-diabetic drugs and the risk of sepsis: a nested case-control study. Sci Rep. 2015;5:1-7.

Liang H, Ding X, Li L. Association of preadmission metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies. Crit Care. 2019;23:1-9.

Shah FA, Mahmud H, Gallego-Martin T. Therapeutic effects of endogenous incretin hormones and exogenous incretin-based medications in sepsis. J Clin Endocrinol Metab. 2019;104:5274-84.

Oh T, Song I. Association between prior metformin therapy and sepsis in diabetes patients: a nationwide sample cohort study. J Anesth. 2020;34:358-66.

Magee F, Bailey M, Pilcher DV, Mårtensson J, Bellomo R. Early glycemia and mortality in critically ill septic patients: Interaction with insulin-treated diabetes. J Crit Care. 2018;45:170-7.

Kushimoto S, Abe T, Ogura H. Impact of blood glucose abnormalities on outcomes and disease severity in patients with severe sepsis: an analysis from a multicenter, prospective survey of severe sepsis. PLoS ONE. 2020;15:1-15.

Van den Berghe G, Wouters P, Weekers F. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-67.

Van den Berghe G, Wilmer A, Milants I. Intensive insulin therapy in mixed medical/surgical intensive care units-benefit versus harm. Diabetes. 2006;55:3151-9.

Salinas PD, Mendez CE. Glucose management technologies for the critically ill. J Diabetes Sci Technol. 2019;13:682-90.

Peake SL, Moran JL, Ghelani DR, Lloyd AJ, Walker MJ The effect of obesity on 12-month survival following admission to intensive care: a prospective study. Crit Care Med. 2006;34:2929-39.

Thomsen RW, Hundborg HH, Lervang HH, Johnsen SP, Sørensen HT, Schønheyder HC. Diabetes and outcome of community-acquired Pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care. 2004;27:70-6.

Esper AM, Moss M, Martin GS. The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study. Crit Care. 2009;13:R18.

Van VughtLA, Holman R, De Jonge E. Diabetes is not associated with increased 90-day mortality risk in critically ill patients with sepsis. Crit Care Med. 2017;45:e1026-35.

Chang CW, Kok VC, Tseng TC. Diabetic patients with severe sepsis admitted to intensive care Unit do not fare worse than non-diabetic patients: a nationwide population-based cohort study. PLoS ONE. 2012;7:1-10.

Leonidou L, Michalaki M, Leonardou A. Stress-induced hyperglycemia in patients with severe sepsis: a compromising factor for survival. Am J Med Sci. 2008;336(6):467-71.

Brunkhorst FM, Engel C, Bloos F. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. New Eng J Med. 2008;358(2):125-39.

Dellinger RP, Levy MM, Rhodes A. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.

COIITSS Study Investigators. Corticosteroid treatment and intensive insulin therapy for septic shock in adults-a randomized controlled trial. J Am Med Asso. 2010;303(17):341-8.

The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Eng J Med. 2009;360(13):1283-97.